Interactions between tricor(fenofibrate) and Dicumarol (dicumarol)
dicumarol and fenofibrate (Major Drug-Drug)
MANAGEMENT: Close clinical and laboratory monitoring for signs of excessive anticoagulation is recommended until the prothrombin time (PT) has stabilized if this combination is used. Some experts recommend decreasing the anticoagulant dose by approximately one-third to one-half in patients receiving concomitant coumarins and fibric acid derivatives with subsequent adjustment based on the PT. Patients should be advised to notify their physicians if they experience any signs of excessive anticoagulation, such as unusual or prolonged bleeding, bruising, vomiting, change in stool or urine color, headache, dizziness, or weakness.






